CHA Medical & Bio Group to Build High-tech Biobank

CHA Medical & Bio Group has begun construction on its cell gene biobank (CGB), housing a variety of high-tech pharmaceutical treatments, manufacturing, and research facilities at Pangyo in Seongnam, Gyeonggi Province, the firm said.


The construction is part of the firm’s efforts to establish a strategy to build a strong, global contract development and manufacturing organization (CDMO) network, alongside Matica Biotechnology, its U.S. cell and gene therapy affiliate with CDMO expertise.

Over $250 million (302 billion won) will be invested to build a 14-story building by 2024 including facilities for a number of CDMOs, as well as partner firms that will take the lead in the development of current good manufacturing practices (cGMP). The practices are required to conform to related guidelines recommended by pharmaceutical products authorization agencies.

Click to read more.

    By submitting to this form, I confirm that I have read and agree to Krishagni's Privacy Policy.

    The 'OpenSpecimen Biobanking LIMS RFP Q&A' Excel is emailed to you.
    Feel free to Contact Us for any questions.

    Srikanth Adiga,
    C.E.0, OpenSpecimen
    Email: sri@krishagni.com


      Avoid Gmail, Yahoo, etc. please.

      By submitting to this form, I confirm that I have read and agree to Krishagni's Privacy Policy.

        By submitting to this form, I confirm that I have read and agree to Krishagni's Privacy Policy.

        The Features PDF has been emailed to you.
        Feel free to "Schedule a Demo" or "Contact Us" for any questions.

        Srikanth Adiga,
        C.E.0, OpenSpecimen
        Email: sri@krishagni.com

          By submitting to this form, I confirm that I have read and agree to Krishagni's Privacy Policy.